Welcome to our dedicated page for AbCellera Biologics SEC filings (Ticker: ABCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbCellera Biologics Inc. filings document regulatory disclosures for a clinical-stage biotechnology company developing antibody-based medicines. Form 8-K reports cover financial and operational results, Regulation FD presentations, ABCL635 clinical program updates, patent settlement and license matters, and leadership or board changes.
Proxy materials describe governance matters, board composition, committee service, director independence, executive compensation, equity awards, and shareholder voting items. The filing record also reflects the company’s status as a British Columbia registrant with securities listed on Nasdaq under the symbol ABCL.
AbCellera Biologics Inc. director Lynn Seely received a grant of share options covering 152,207 common shares. The options have an exercise price of $7.85 per share and expire on July 1, 2036. They vest in three equal annual installments beginning July 1, 2027, contingent on continued service.
AbCellera Biologics Inc. director Lynn Seely has filed a Form 3, which is an initial statement of beneficial ownership for insiders. The structured data for this filing shows no reported transactions in AbCellera securities and no listed derivative positions for the reporting person.
AbCellera Biologics Inc. director Sandor Victor received a grant of options covering 152,207 common shares on July 1, 2026. These share options have an exercise price of $7.85 per share and expire on July 1, 2036.
The options vest in three substantially equal annual installments, with the first tranche scheduled to vest on July 1, 2027, subject to his continued service with the company. After this grant, he holds options on 152,207 shares directly.
AbCellera Biologics Inc. has appointed Lynn Seely, M.D., as a new Class III independent director on its Board of Directors. She will serve until the company’s 2029 annual meeting of shareholders and until a successor is elected and qualified or she departs earlier.
The Board determined that Dr. Seely is independent under Nasdaq rules and the company’s corporate governance guidelines. She will receive compensation under AbCellera’s Non-Employee Director Compensation Policy on the same terms as other non-employee directors, with no related-party transactions or appointment arrangements disclosed.
Dr. Seely is president and CEO of Lyell Immunopharma Inc. and previously led Myovant Sciences Inc. and served as chief medical officer of Medivation Inc., where she oversaw development of the oncology drug Xtandi. A press release with additional background is included as Exhibit 99.1.
AbCellera Biologics Inc. entered a preclinical research collaboration, option and license agreement with Jazz Pharmaceuticals to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. The collaboration includes $56 million in upfront payments to AbCellera for two initial programs, with a commitment to start a third program within 12 months. AbCellera will receive an additional $28 million upon initiation of the third program and is eligible for up to $792 million per program in option fees and development, regulatory and commercial sales milestone payments, plus tiered royalties on net sales ranging from mid-single digits to low double-digits.
AbCellera Biologics Inc. director Michael R. Hayden received a grant of share options covering 111,701 common shares. The options have an exercise price of $5.27 per share, expire on June 11, 2036, and represent compensation rather than an open-market purchase.
The options vest and become exercisable at the company’s 2027 Annual General Meeting, subject to his continuous service with AbCellera through that date. Following this award, he holds options on a total of 1,011,544 underlying common shares directly.
AbCellera Biologics Inc. director Stephen Quake received a grant of 111,701 share options giving the right to buy an equal number of common shares at an exercise price of $5.27 per share. After this grant, Quake holds share options for a total of 306,633 common shares.
The options vest and become exercisable at the company’s 2027 Annual General Meeting, provided Quake continues to serve the company through that date. This is a compensation-related award rather than an open-market stock trade.
AbCellera Biologics Inc. director John S. Montalbano received a grant of share options giving him the right to buy 111,701 common shares at an exercise price of $5.27 per share. These options vest and become exercisable at the 2027 Annual General Meeting, as long as he continues serving the company. After this grant, he holds 1,141,544 share options in total.
AbCellera Biologics Inc. reported the results of its annual shareholder meeting held on June 11, 2026. Shareholders elected Class III directors John S. Montalbano and Stephen R. Quake to terms ending at the 2029 annual meeting. As of the April 15, 2026 record date, 305,264,947 common shares were outstanding and entitled to vote.
Shareholders also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers (Say-on-Pay). No other matters were submitted for a vote.
AbCellera Biologics Inc. filed an initial ownership report for Sandor Victor. The filing identifies him as a director of the company, not an officer and not a ten percent owner. This Form 3 does not report any share transactions or holdings, serving only as a baseline disclosure.